Takeda has licensed exclusive worldwide rights to develop and commercialise Finch Therapeutics' inflammatory bowel disease (IBD) candidate, FIN-524, and any follow-on products for an upfront payment of US$10 M. FIN-524 leverages Finch’s discovery platform and designed based on favourable clinical outcomes in studies of microbiota transplants in IBD. Takeda has been strengthening its pipeline in the gastrointestinal disease area by investing in new therapeutics for the treatment of gastric disorders.